首页> 外文期刊>Journal of experimental & clinical cancer research : >Plasma levels of leptin and soluble leptin receptor and polymorphisms of leptin gene -18G > A and leptin receptor genes K109R and Q223R, in survivors of childhood acute lymphoblastic leukemia
【24h】

Plasma levels of leptin and soluble leptin receptor and polymorphisms of leptin gene -18G > A and leptin receptor genes K109R and Q223R, in survivors of childhood acute lymphoblastic leukemia

机译:儿童急性淋巴细胞白血病幸存者的瘦素和可溶性瘦素受体血浆水平以及瘦素基因-18G> A和瘦素受体基因K109R和Q223R的多态性

获取原文
       

摘要

Background Approximately 20% of children and adolescents in Europe are overweight. Survivors of pediatric acute lymphoblastic leukemia (ALL) are at increased risk of overweight and obesity. The purpose of this study was to assess leptin and leptin soluble receptor levels, as well as polymorphisms of selected genes in survivors of pediatric ALL, and the influence of chemo- and radiotherapy on development of overweight in the context of leptin regulation. Methods Eighty two patients (55% males), of median age 13.2 years (m: 4.8 years; M: 26.2 years) were included in the study. The ALL therapy was conducted according to modified Berlin-Frankfurt-Munster (BFM; n = 69) regimen or New York (n = 13) regimen. In 38% of patients cranial radiotherapy (CRT) was used in median dose of 18.2Gy (m: 14Gy; M: 24Gy). Median age at diagnosis was 4.5 (m: 1 year; M: 16.9 years) and median time from completion of ALL treatment was 3.2 years (m: 0.5 year; M: 4.3 years). Patients with BMI ≥85 percentile were classified as overweight. Correlation of plasma levels of leptin and leptin soluble receptor, and polymorphisms of leptin gene -18G > A, leptin receptor genes K109R and Q223R, and the overweight status were analyzed in relation to gender, intensity of chemotherapy (high intensity vs. standard intensity regimens) and to the use of CRT. Results Significant differences of leptin levels in patients treated with and without CRT, both in the entire study group (22.2+/- 3.13 ng/ml vs. 14.9+/-1.6 ng/ml; p Conclusions The prevalence of overweight in our cohort was higher than in general European population (31% vs 20%) and increased regardless of the use of CRT. Leptin and leptin receptor levels may be used as useful markers of high risk of becoming overweight in ALL survivors, particularly in females treated with CRT. Polymorphisms of leptin gene -18G > A and leptin receptor genes K109R and Q223R were not associated with overweight status in ALL survivors.
机译:背景资料在欧洲,大约20%的儿童和青少年超重。小儿急性淋巴细胞白血病(ALL)的幸存者超重和肥胖的风险增加。这项研究的目的是评估瘦素和瘦素可溶性受体水平,以及小儿ALL幸存者中所选基因的多态性,以及在瘦素调节的情况下化学疗法和放射疗法对超重发展的影响。方法研究对象为中位年龄13.2岁(男:4.8岁;男:26.2岁)的82例患者(男55%)。 ALL治疗是根据改良的Berlin-Frankfurt-Munster(BFM; n = 69)方案或New York(n = 13)方案进行的。在38%的患者中,颅骨放射疗法(CRT)的中位剂量为18.2Gy(m:14Gy; M:24Gy)。诊断时的中位年龄为4.5(m:1年; M:16.9岁),完成ALL治疗的中位时间为3.2年(m:0.5年; M:4.3年)。 BMI≥85%的患者被归类为超重。分析了瘦素和瘦素可溶性受体的血浆水平,瘦素基因-18G> A,瘦素受体基因K109R和Q223R的多态性以及超重状态与性别,化疗强度(高强度vs.标准强度方案)的相关性)并使用CRT。结果在整个研究组中,接受和不接受CRT的患者中的瘦素水平均存在显着差异(22.2 +/- 3.13 ng / ml与14.9 +/- 1.6 ng / ml; p结论)高于欧洲普通人群(分别为31%和20%),并且无论是否使用CRT都增加了;瘦素和瘦素受体水平可以用作所有幸存者特别是接受CRT治疗的女性中超重的高风险的有用标志。瘦素基因-18G> A和瘦素受体基因K109R和Q223R的多态性与所有幸存者的超重状态无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号